Find Funding Opportunities

The purpose of this Brain Research through Advancing Innovative Neurotechnologies (BRAIN) Initiative is to encourage applications that will develop and validate tools and resources to facilitate the detailed analysis of brain microconnectivity. Novel and augmented techniques are sought that will ultimately be broadly accessible to the neuroscience community for the interrogation of microconnectivity in healthy and diseased brains of model organisms and humans. Development of technologies that will significantly drive down the cost of connectomics would enable routine mapping of the microconnectivity on the same individuals that have been analyzed physiologically, or to compare normal and pathological tissues in substantial numbers of multiple individuals to assess variability. Advancements in both electron microscopy (EM) and super resolution light microscopic approaches are sought. Applications that propose to develop approaches that break through existing technical barriers to substantially improve current capabilities are highly encouraged. Proof-of-principle demonstrations and/or reference datasets enabling future development are welcome, as are improved approaches for automated segmentation and analysis strategies of neuronal structures in EM images.no

The purpose of the FOA is to support unbiased proteomics analysis of matched longitudinal CSF and plasma samples from the Accelerating Medicine Partnership in Parkinson's disease (AMP PD) cohorts using a data independent acquisition (DIA) mass spectrometry platform, with the ultimate goal of identifying PD biomarkers for diagnosis, prognosis and progression. Proteomics data and workflows generated through this initiative will be broadly shared with the research community through the AMP PD Knowledge Portal to enable additional analyses and data integration across the various datatypes available through AMP PD. The proteomics analysis will be staged to include identification of pre-analytical variables, that will inform the optimal handling of 4,500 CSF and plasma samples.

NIDA and the following NIH Institutes and Centers (ICs), NIAAA, NICHD, NIMH, NIMHD, NINDS, OBSSR, and NCI intend to publish a Collaborative Research on Addiction at NIH (CRAN) funding opportunity announcement to solicit applications for a Data Analysis, Informatics, and Resource center to oversee and manage the standardization of data collection procedures, provide technical support, ensure quality control, perform integrative data analysis, and coordinate data storage and data sharing activities for a nationwide, multisite, multi-modal, longitudinal cohort study that prospectively examines brain and behavioral development from late childhood (approximately age 9-10) through adolescence into early adulthood. Current primary awardees will be eligible to apply and this new award period will be extended to 7 years in duration.

NIDA and the following NIH Institutes and Centers (ICs), NIAAA, NICHD, NIMH, NIMHD, NINDS, OBSSR, and NCI intend to publish a limited competition Collaborative Research on Addiction at NIH (CRAN) funding opportunity announcement to solicit applications for a Coordinating Center in service of a nationwide, multisite, multi-modal, longitudinal cohort study to prospectively examine brain and behavioral development from late childhood (approximately age 9-10) through adolescence into early adulthood. Current primary awardees will be eligible to apply and this new award period will be extended to 7 years in duration.

NIDA and the following NIH Institutes and Centers (ICs), NIAAA, NICHD, NIMH, NIMHD, NINDS, OBSSR, and NCI intend to publish a Collaborative Research on Addiction at NIH (CRAN) funding opportunity announcement to solicit applications for research project sites in service of a nationwide, multisite, multi-modal, longitudinal cohort study to prospectively examine brain and behavioral development from late childhood (approximately age 9-10) through adolescence into early adulthood. Current primary awardees will be eligible to apply and this new award period will be extended to 7 years in duration.

Notice Availability Administrative Supplements the INCLUDE Investigation Co-occurring Conditions across Lifespan Understand Down syndromE) Project Administrative Supplement/ Clinical Trial Optional) Notice Number: NOT-OD-19-087 Key Dates Release Date: March 27, 2019 Related Announcements PA-18-591 NOT-OD-19-071NOT-OD-20-012> RFA-OD-19-015 RFA-OD-19-016 RFA-OD-19-018 Issued National Institutes Health NIH) National Cancer Institute NCI) National Eye Institute NEI) National Heart, Lung, Blood Institute NHLBI) National Human Genome Research Institute NHGRI) National Institute Aging NIA) National Institute Allergy Infectious Diseases NIAID) National Institute Arthritis Musculoskeletal Skin Diseases NIAMS) Eunice Kennedy Shriver National Institute Child Health Human Development NICHD) National Institute Deafness Other Communication Disorders NIDCD) National Institute Environmental Health Sciences NIEHS) National Institute General Medical Sciences NIGMS) National Institute Neurological Disorders Stroke NINDS) National Institute Nursing Research NINR) National Center Complementary Integrative Health NCCIH) National Center Advancing Translational Sciences NCATS) Division Program Coordination, Planning Strategic Initiatives, Office Research Infrastructure Programs ORIP) Office Strategic Coordination Common Fund) Purpose National Institutes Health Office the Director announces opportunity investigators relevant active NIH-supported research project grants the participating Institutes listed above submit administrative supplement applications funded projects meet new NIH Down syndrome research objectives related the NIH INvestigation Co-occurring conditions across Lifespan Understand Down syndromE INCLUDE) Project https://www.nih.gov/include-project). notice soliciting administrative supplements the following mechanisms ONLY: Resource-Related Research Projects R24), Research Program Projects Centers P01, P30, P50) cooperative agreements U10, U19, U24, U54, UG1, UG3, UL1 ) Resource-Related Research Multi-Component Projects Centers Cooperative Agreements U2C), training programs T32). Down syndrome the most common genetic cause intellectual disability, most common autosomal trisomy, one the most visible universally recognized genetic syndromes. year are approximately 5300 babies born the United States Down syndrome. Within past 25 years, average lifespan a person Down syndrome doubled, 30 60 years. While people Down syndrome connected the common feature a complete partial copy chromosome 21 trisomy 21), are significant physical cognitive differences among them, indicating inter-individual variability exists. this notice, NIH continuing support a program research Down syndrome initiated FY2018 support research commonly co-occurring conditions individuals Down syndrome are also seen the general population, such Alzheimer’s disease/dementia, autism, cataracts, celiac disease, congenital heart disease diabetes. is known the INCLUDE Project (INvestigation Co-occurring conditions across Lifespan Understand Down syndromE). Information learned studying people Down syndrome also help us learn these conditions people without Down syndrome. Likewise, common complications aging, such coronary heart disease solid cancers, rarely seen individuals Down syndrome; warrants additional study. new research initiative expands of research objectives opportunities previously highlighted the 2014 Down Syndrome Directions: NIH Research Plan Down Syndrome. recent discoveries enhanced our understanding chromosome segregation chromosome silencing, identified certain proteins neurotropic factors involved brain development using mouse models, uncovered role interferons immune dysregulation, of have potential lead development novel therapies individuals Down syndrome, well broader applications. People Down syndrome often excluded clinical research, such trials potentially beneficial drugs therapeutics are used treat same condition the general population. is great value connecting people Down syndrome therapies could improve overall health quality life. there great interest the Down syndrome community participating clinical research, based experience NICHD’s DS-Connect®: Down Syndrome Registry®,” https://DSConnect.nih.gov), online survey tool introduces individuals Down syndrome their families research opportunities. comprehensive clinical cohort study deep phenotyping exploration pan-‘omics permit identification biomarkers outcomes the co-occurring conditions Down syndrome. Coupled development a clinical trials readiness program, informed basic science discoveries, combination resources have great impact addressing health disparities exist people Down syndrome could also lead the development therapies improve outcomes those and without condition. Supplement applications be considered eligible funding they address or of following components related the INCLUDE Project research objectives: Component 1: Targeted, high risk-high reward, basic science studies Down syndrome: basic science studies, supplements should target areas science highest impact. Topics emphasis include: chromosome silencing, immune system dysregulation, epigenetic/metabolomic/transcriptomic profiling model organisms/iPSCs/brain organoids, development novel model systems, development a molecular atlas cardiac other specimens. Supplements also support projects will inform other components, namely cohort study a clinical trials network. Component 2: Molecular snapshot Down syndrome through cohort study: goal to add or expand existing Down syndrome cohort, data collected a shared database using common data elements building the DS-Connect® patient registry. Supplements add comprehensive molecular i.e., pan-‘omics) analyses existing Down syndrome cohorts support existing infrastructure sample neuroimaging collection the Down syndrome population. Component 3: Inclusive clinical research individuals Down syndrome: Supplement requests leverage existing clinical trials infrastructure expand extend existing DS cohort a currently funded trial build component(s) an existing clinical trials infrastructure includes Down syndrome could expanded accommodate additional Down syndrome clinical trials the future. Applications be considered eligible funding they: within scope the active parent award focused Down syndrome Propose address of components listed under Down syndrome research objectives likely stimulate additional activity leading progress Down syndrome Address priority the IC issued parent award applicable--see below) Investigators should submit applications responses the parent active administrative supplement PA, Administrative Supplements Existing NIH Grants Cooperative Agreements Parent Admin Supp Clinical Trial Optional)”: https://grants.nih.gov/grants/guide/pa-files/PA-18-591.html Supplements existing clinical trials allowed. proposed research must within scope the parent clinical trial the parent clinical trial award must two more budget years remaining the current project period . addition a new clinical trial was a part the parent award not allowed. Supplement requests addressing components 2 3 should encourage participants Down syndrome their caregivers register DS-Connect®: Down Syndrome Registry https://DSConnect.nih.gov). Before submitting supplement request, principal investigators strongly encouraged contact program officer the program contact the Institute, Center Office supporting parent award any questions to discuss whether proposed supplement within scope the parent award, focused the goals the INCLUDE Project consistent the priorities the IC supporting parent award. Award Project Period be eligible, parent award must active FY19 i.e., parent award received funds FY19 is in extension period), the research proposed the supplement should requested 1 year. awarding institute consider no-cost extension up an additional year the conclusion the first year. earliest anticipated start date August 1, 2019. Budget Supplement budget requests exceed 500,000 direct costs 50% the direct costs the current year the parent award exclusive Facilities Administrative costs sub-contracts), must receive permission the project officer IC Contact listed below prior submission. Requests must reflect actual needs the proposed project. Modular categorical budgets permitted. Eligible Individuals Program Director/Principal Investigator) Individual(s) must hold active grant cooperative agreement. supplements parent awards include multiple PDs/PIs, supplement be requested any all the PDs/PIs accordance the existing leadership plan) submitted the awardee institution the parent award. Submitting Application order ensure identification, tracking, appropriate review their applications, applicants MUST follow special instructions Applications must be submitted electronically through NIH ASSIST module, institutional system-to-system S2S) solution, Grants.gov Workspace, must include"NOT-OD-19-087" without quotation marks) the Agency Routing Identifier field Box 4B) the SF424 R&R form. Applications without identifier Box 4B not considered this special initiative. multi-component awards, administrative supplements should prepared a single project using FORMS-E-ADMINISUPP RESEARCH project. T32 awards should FORMS-E-ADMINISUPP TRAINING. addition, applicants strongly encouraged notify Program contact the Institute is supporting parent award list below) an application been submitted response this Notice order facilitate efficient processing the request. application Abstract section should describe proposed supplement, the Research Strategy section should include summary abstract the funded parent award project. Research Strategy should state relevance the parent award the INCLUDE project, articulate component(s) any IC-specific priorities the supplement addressing. additional information, the parent program announcement Administrative Supplements Existing NIH Grants Cooperative Agreements Parent Admin Supp Clinical Trial Optional) PA-18-591. Page Limits: NIH consider supplements a Research Strategy of no than 6 pages, addition the abstract. Requests must received 5:00 PM Pacific Daylight Time P.D.T.) May 24 , 2019 funding FY 2019. Frequently Asked Questions FAQs) listed the INCLUDE website information specific scientific priorities program contacts the NIH participating ICs https://www.nih.gov/include-project). Inquiries Please direct inquiries the contact the Institute, Center Office supporting parent award: Malcolm A. Smith, MD, PhD National Cancer Institute NCI) Telephone: 240-276-6087 Email:Malcolm.Smith@nih.gov Houmam Araj, PhD National Eye Institute NEI) Telephone: 301-451-2020 Email:arajh@nei.nih.gov Charlene Schramm, PhD National Heart, Lung, Blood Institute NHLBI) Telephone: 301-402-3793 Email:SchrammC@nhlbi.nih.gov Joy T. Boyer, BA National Human Genome Research Institute NHGRI) Telephone: 301-480-2247 Email:jb40m@nih.gov Laurie M. Ryan, PhD National Institute Aging NIA) Telephone: 301-496-9350 Email:ryanl@mail.nih.gov Frosso Voulgaropoulou, PhD National Institute Allergy Infectious Diseases NIAID) Telephone: 240-627-3205 Email:fvoulgaropoulou@niaid.nih.gov Marie Mancini, PhD National Institute Arthritis Musculoskeletal Skin Diseases NIAMS) Telephone: 301-594-5032 Email: mancinim2@mail.nih.gov Melissa A. Parisi, MD, PhD Eunice Kennedy Shriver National Institute Child Health Human Development NICHD) Telephone: 301-435-6880 Email: parisima@mail.nih.gov Kelly King, PhD National Institute Deafness Other Communication Disorders NIDCD) Telephone: 301-402-3458 Email: kingke@nidcd.nih.gov Jonathan A. Hollander, PhD National Institute Environmental Health Sciences NIEHS) Telephone: 984-287-3269 Email:jonathan.hollander@nih.gov Donna Krasnewich, MD, PhD National Institute General Medical Sciences NIGMS) Email: dkras@nigms.nih.gov Robert Riddle, PhD National Institute Neurological Disorders Stroke NINDS) Telephone: 301-496-5745 Email: rr260c@nih.gov Rebekah S. Rasooly, PhD National Institute Nursing Research NINR) Telephone: 301-827-2599 Email:rr185i@nih.gov Erica Rosemond, Ph.D National Center Advancing Translational Sciences NCATS) Telephone: 301-594-8927 Email:rosemonde@mail.nih.gov Robin Boineau, MD, MA National Center Complementary Integrative Health NCCIH) Telephone: 301-435-6286 Email: Robin.Boineau@nih.gov Sige Zou, PhD Office Research Infrastructure Programs ORIP) Telephone: 301-435-0749 Email: sige.zou@nih.gov Concepcion Marie) Nierras, PhD Office Strategic Coordination Common Fund) Telephone: 301-435-5840 Email: concepcion.nierras@nih.gov  

The purpose of the NINDS Institutional Translational Research Training Program is to equip trainees with the knowledge and skills needed to advance basic research toward clinical application. These programs will support, students and/or postdocs conducting basic, disease-relevant research in an environment that includes 1) basic neuroscientists and clinicians who are actively engaged in collaborative research projects, 2) neuroscience researchers with expertise in translational processes who are conducting research designed to move basic discoveries toward clinical application and 3) relationships with industry and government regulatory agencies. Programs will have a cohesive educational approach to translational training in areas relevant to the NINDS mission, and in which students and postdocs learn the processes involved in translational research in the context of their individual projects. Programs supported by this FOA must include activities that ensure a thorough understanding of experimental design, strong statistical and analytical skills, and skills for communicating science with a wide variety of audiences. These programs are intended to be 2 years in duration and support training of one or more of the following groups: advanced predoctoral students, postdoctoral fellows and fellowship-stage clinicians. Upon completion of the program, trainees will be prepared to address basic research problems with an understanding of the requirements for translating discoveries into viable therapies.

This Funding Opportunity Announcement (FOA) invites researchers to submit applications for support of clinical studies that address critical needs for clinical trial readiness in rare neurological and neuromuscular diseases. These studies should result in clinically validated biomarkers and clinical outcome assessment measures appropriate for use in upcoming clinical trials. Through the support of trial readiness studies, NINDS and NCATS expect to enhance the quality and increase the likelihood of success of clinical trials in these rare diseases.

This is the renewal of a Funding Opportunity Announcement (FOA), issued by NICHD, NINDS, NIBIB, NIDCD, and NINR, National Institutes of Health, to invite grant applications from institutions/organizations that propose to build a research infrastructure center to promote external collaboration with the medical rehabilitation community. The aim of this FOA is to create a national network of research centers that provide access to collateral expertise in biomedical, behavioral, engineering, and/or psychosocial fields that are particularly relevant to medical rehabilitation research and the needs of people with chronic physical disabilities. Specifically, the NIH is interested in addressing gaps in the rehabilitation research portfolio and is particularly interested in the following high-priority areas: pediatric rehabilitation; personalized medicine approaches; family, caregiver, and community support; implementation and dissemination research; clinical trial design and combinatorial therapies; strategies to explore and validate combination therapies; and, technology to track real-world outcomes.

Notice Special Interest Research the Health Sexual Gender Minority SGM) Populations Notice Number: NOT-MD-19-001 Key Dates Release Date: March 13, 2019 Related Announcements None Issued National Institute Minority Health Health Disparities NIMHD) National Center Complementary Integrative Health NCCIH) National Cancer Institute NCI) National Human Genome Research Institute NHGRI) National Heart, Lung, Blood Institute NHLBI) National Institute Aging NIA) National Institute Alcohol Abuse Alcoholism NIAAA) National Institute Allergy Infectious Diseases NIAID) National Institute Arthritis Musculoskeletal Skin Diseases NIAMS) Eunice Kennedy ShriverNational Institute Child Health Human Development NICHD) National Institute Drug Abuse NIDA) National Institute Dental Craniofacial Research NIDCR) National Institute Diabetes Digestive Kidney Diseases NIDDK) National Institute Environmental Health Sciences NIEHS) National Institute Mental Health NIMH) National Institute Neurological Disorders Stroke NINDS) Office Behavioral Social Sciences Research OBSSR) Office Disease Prevention ODP) Office Research Womens Health ORWH) Sexual & Gender Minority Research Office SGMRO) Purpose Notice calls research the health sexual gender minority populations. Sexual gender minority" an umbrella term encompasses lesbian, gay, bisexual, transgender populations well those whose sexual orientation, gender identity expressions, reproductive development varies traditional, societal, cultural, physiological norms. includes individuals disorders differences sex development DSD), sometimes known intersex. Although has an increase SGM-focused health research recent years, remains need further research the health these populations. Notice encourages research describes biological, clinical, behavioral, social processes affect health development SGM populations individuals their families, that leads the development acceptable appropriate health interventions health service delivery methods will enhance health development these populations. Types research are relevant this Notice include, are limited to: Epidemiological research examines patterns risk, morbidity mortality related diseases health conditions have been adequately studied SGM populations. Etiological mechanistic research examining biological, behavioral, social, and/or environmental factors contribute health outcomes health disparities SGM populations. Research leading interventions ameliorate health disparities SGM populations, including formative research identify develop appropriate intervention content well pilot testing interventions establish feasibility, acceptability, preliminary efficacy. Large-scale design, implementation evaluation preventive and/or treatment interventions addressing health issues SGM populations. Possible funding opportunity announcements FOAs) their re-issues which SGM-related research be submitted include are limited Parent FOAs Research R), Career Development K), Fellowship F) awards Parent Announcements Unsolicited Investigator Initiated Applications)":https://grants.nih.gov/grants/guide/parent_announcements.htm. Applicants should carefully note participating Institutes/Centers each FOA. Applications must in mission an Institute/Center listed Components Participating Organizations the FOA. Offices listed this Notice consider co-funding applications assigned an Institute/Center participates the FOA. Investigators strongly encouraged reach to relevant contacts listed below identify FOAs be most appropriate their proposed project application. Applicants should indicate Notice number NOT-MD-19-001) Field 4.b the SF 424 application form refer NOT-MD-19-001 the abstract assist identifying applications submitted this Notice. Areas programmatic interest toNIMHDinclude are limited to: Observational studies how social determinants, such minority stress, stigma discrimination, lack access culturally competent healthcare, social networks, social support, cause, sustain, ameliorate health disparities. Epidemiological studies the relationship between intersectionality SGM status other health disparity population membership health outcomes. addition SGM populations, NIH-designated health disparity populations include racial/ethnic minorities, socioeconomically disadvantaged populations, underserved rural populations. Intervention studies community healthcare settings reduce health disparities. NIMHDencourages projects use approaches encompass multiple domains e.g., biological, behavioral, socio-cultural, environmental, physical environment, health system) multiple levels e.g., individual, interpersonal, community, societal) understand address health disparities SGM populations the NIMHD Research Framework,https://www.nimhd.nih.gov/about/overview/research-framework.html, examples health determinants interest). Animal studies studies focused SGM populations outside the US not priorities NIMHD under Notice. NCCIHis interested supporting research the of complementary integrative health approaches, including natural products mind body interventions, manage stress, chronic pain, mild anxiety, depression among SGM populations. NCCIH also interested research studying mind body approaches improve adherence treatment e.g., Medication Assisted Treatment MAT) opioid misuse, Antiretroviral therapy ART) HIV) prevention e.g., Pre-exposure prophylaxis PrEP) HIV) regimens promote health outcomes. Natural products include botanicals, pre/probiotics, products marketed dietary supplements. Mind body approaches include various meditation approaches e.g., mindfulness), hypnosis guided imagery, meditative movement approaches e.g., yoga, tai chi, qi-gong), body-based approaches e.g., spinal manipulation, massage, mobilization, acupuncture), combination these approaches e.g., meditation yoga, such in mindfulness-based stress reduction MBSR), complex interventions including music art therapy. NCCIH offers range funding opportunity announcements support clinical trials natural products mind body interventions. Applicants strongly encouraged consult the NCCIH Scientific Research contact prior developing submitting application. Areas programmatic interest toNCIinclude are limited to) studies that: Identify cancer health care needs across cancer continuum, including prevention, early detection, diagnosis, treatment, survivorship, end life care among SGM populations; Increase understanding the cancer care needs, health outcomes effective interventions improve outcomes SGM individuals; Assess cancer risk inform improved decision-making, risk reduction interventions, screening options early cancer detection SGM populations; Evaluate interventions increase rates screening, follow-up, referral-to-care, improve symptom management cancer prevention control among SGM populations; Increase understanding the barriers cancer health care information treatment may lead SGM individuals/populations avoid delay seeking health care; Examine relative risk cancer cancer risk factors e.g., smoking, obesity, aging, infections such HPV HIV, tobacco use, alcohol consumption, nulliparity) underlying mechanisms risk social, behavioral, biological, clinical) SGM groups comparison their heterosexual counterparts; Investigate cancer patient outcomes, cancer treatment delivery, healthcare utilization SGMs; Improve understanding the differential risks certain types cancers including cervical, breast, ovarian, anal, other malignancies among SGMs; Examine potential cancer risks hormone therapy including off-label use) among transgender and/or intersex individuals; Investigate prevalence rates HPV infection SGM groups the development screening interventions and/or recommendations ameliorate HPV-associated disease; Examine intersection contextual factors e.g., race, geography, socioeconomic status) cancer health outcomes across SGM groups; Investigate lack access and utilization cancer health care services, quality care received, SGM populations impact health outcomes; Assess impact stigma, discrimination, victimization, substance use, other risk factors utilization cancer preventive screening/services; Investigate positive and/or protective factors e.g., family and/or social support) cancer prevention. Areas programmatic interest toNHGRIinclude are limited to: Development resources, approaches, technologies will accelerate genomic research the structure genomes, biology genomes, the biology disease; Developments will genomics advance science medicine, that incorporate genomics improve effectiveness healthcare; Research several cross-cutting areas, including ethical, legal societal implications genomics research, bioinformatics, research training career development. NHLBIprovides global leadership a research, research training, education program promote prevention treatment heart, lung, blood, sleep diseases enhance health all individuals that can live longer more fulfilling lives. NHLBI encourages research designed answer breadth scientific questions related heart, lung, blood, and/or sleep diseases, disorders, phenotypes. NHLBI seeks research applications(R01 applications only)that address questions relevant the NHLBI mission, address gaps the NHLBIs portfolio clinical epidemiology cohort studies should align the NHLBIs Strategic Vision. NHLBIs strategic priorities emphasize continuum research basic molecular biology research implementation science related heart, lung, blood, sleep disorders e.g., Sickle Cell Disease other hemoglobinopathies; cardiovascular diseases; hypertension prevention control; asthma; chronic obstructive pulmonary disease COPD); sleep apnea; other cardiopulmonary diseases conditions), self-management symptoms disease conditions, prevention these diseases disorders various populations. NHLBI also significant interests implementation science research the prevention, control, treatment heart, lung, blood diseases, sleep disorders, particularly research addresses development interventions strategies address translation proven-effective, evidence-based interventions clinical, community, and/or settings; addresses impediments uptake, scale up, sustainability evidence-based research. Please refer the NHLBI website more details the research priorities the NHLBI:https://www.nhlbi.nih.gov/about/documents/strategic-vision. NIAis interested research can improve understanding aging processes andexperiences impact health well-being middle-aged older SGM adults well studies focused early life exposures contribute SGM health disparities adulthood. NIA encourages of multi-level analysis individual, dyadic, family, community/institution, population data, consideration multidimensional measures sexual orientation identity, attraction, behavior) diverse gender categories. NIA supports cross-national studies better understand aging experience a global level the effects various policies. Natural experiments, arising policy change regional differences, provide another powerful approach examining mechanisms affecting health SGM older adults. Applicants encouraged leverage NIAs investment data infrastructure publicly available datasets. NIAsOffice Research Resources.) Areas programmatic interest toNIAinclude are limited to: Studies examining interpersonal processes, the situational contexts influence them, lead positive healthy relationships adulthood older age. NIA especially interested research can identify causal mechanisms accounting links between marital status, long-term romantic partnerships, health. Studies examining factors such social identity, intersectionality, positionality, stigma impact interpersonal interactions, well-being, health later life. Causes consequences self-disclosing sexual orientation gender identity mid-late life older age families, intimate partners, employers, health care practitioners, institutions. Studies unique caregiving needs older SGM individuals, especially, individuals Alzheimers disease related dementias their families origin chosen). Interventions promote healthy aging reduce health disparities SGM adults.NIA encourages mechanism-focused approach intervention development promoted theNIH Science Behavior Changeand theNIH Stage Model. NIA also supports pragmatic trial development Introduction pragmatic clinical trials"). Data infrastructure method development support studies older SGM adults, including development representative population cohorts older SGM adults adequate sample size study issues intersectionality, the addition cohort-sensitive SGM measures existing studies. includes development novel recruitment strategies methods approaches identifying assessing unique issues needs older SGM adults. NIAAAseeks innovative applications the areas of: Epidemiological research examines patterns risk, morbidity mortality related alcohol disorders AUDs) SGM populations, including studies 1) risk protective factors heavy including binge) drinking AUDs; 2) correlates underage drinking related problems among SGM populations; 3) factors influence transitions and of problem drinking patterns across lifespan among SGM populations; 4) consequences, drinking related problems, may attributable the combination racial/ethnic minority status addition SGM status. Etiological mechanistic researchincluding human laboratory-based researchexamining biological, behavioral, social, and/or environmental factors contribute drinking-related outcomes SGM populations. Research leading interventions ameliorate drinking related problems SGM populations, including formative research identify develop appropriate intervention content well pilot testing interventions establish feasibility, acceptability, preliminary efficacy. Design, implementation evaluation preventive and/or treatment interventions address AUDs related problems that appropriate the needs SGM populations. Such projects extend evaluations screening, assessment, brief interventions, referral alcohol treatment; other individual-level preventive approaches, such protective strategies; studies assess drinking prevention approaches enlist families peers online offline); studies focus the effects community/institutional-level alcohol policies preventing drinking related problems among SGM populations; studies look alcohol treatment efficacy among SGM populations. Areas programmatic interest toNIAIDinclude are limited to: Research all areas HIV infection, including developing testing preventive HIV vaccines, other prevention strategies, new treatments HIV infection AIDS-associated opportunistic infections Basic applied research better understand, treat, ultimately prevent infectious, immunologic, allergic diseases. Training career development e.g. T, F, K) applications rural urban institutions may underserved SGM populations. mission ofNIAMSis support research the causes, treatment, prevention arthritis musculoskeletal skin diseases; training basic clinical scientists carry this research; the dissemination information research progress these diseases. NIAMS also conducts supports basic research the normal structure function bones, joints, muscles, skin. Basic research involves wide variety scientific disciplines, including immunology, genetics, molecular biology, structural biology, biochemistry, physiology, virology, pharmacology. Clinical research areas include rheumatology, orthopaedics, dermatology, metabolic bone diseases, heritable disorders bone cartilage, inherited inflammatory muscle diseases, sports rehabilitation medicine. NIAMS also seeks studies include sufficient numbers SGM individuals enable robust sub-group analyses. Clinical trials designed answer specific questions the safety, tolerability, efficacy, effectiveness, clinical management, and/or implementation pharmacologic, behavioral, biologic, surgical, device invasive non-invasive) interventions only supported NIAMS submitted a NIAMS clinical trials-specific FOA. current list active NIAMS clinical trials FOAs available athttps://www.niams.nih.gov/grants-funding/conducting-clinical-research/g…. information regarding NIAMS supported scientific areas/programs contacts, please see:https://www.niams.nih.gov/grants-funding/supported-scientific-areas. TheNICHDsupports biological, behavioral, clinical research related conception pregnancy, normal abnormal development childhood, reproductive health, population dynamics across lifespan, rehabilitation medicine https://www.nichd.nih.gov/grantsfunding/opportunities-mechanisms/areas-…). Research projects considered funding NICHD must fall within scientific missions the twelve Scientific Branches the NICHD Division Extramural Research DER) the National Center Medical Rehabilitation Research NCMRR). Information those scientific missions program staff contacts be found the web pages the DER scientific branches at:http://www.nichd.nih.gov/about/org/der/branches/Pages/index.aspxand NCMRR at:http://www.nichd.nih.gov/about/org/ncmrr/Pages/overview.aspx. Potential applicants strongly encouraged read webpages any updates response recent scientific advances emerging public health topics. NICHD encourages applications address extramural program priorities will consider well research projects align one more those priorities making award decisions. detailed list NICHD high priority research areas be found athttps://www.nichd.nih.gov/grants-funding/opportunities-mechanisms/areas… Areas programmatic interest toNIDAinclude are limited to: Innovative drug abuse epidemiology, prevention, health services research among SGM populations; Translational research applies findings epidemiology, cognitive science, neuroscience, other sciences develop test novel prevention interventions among SGM populations; Treatment development research testing substance disorders, including behavioral treatments, among SGM populations; Vulnerability addiction biological etiology among SGM populations; Behavioral cognitive mechanisms consequences substance polysubstance among SGM populations. Areas programmatic interest toNIDCRinclude are limited to: Research craniofacial skeletal tissue homeostasis, injury, repair the presence hormone therapy Epidemiologic research the prevalence unmet dental, oral, and/or craniofacial needs SGM individuals, e.g., oral cancers, oral complications HIV/AIDS, orofacial trauma Research identifying explanatory mechanisms oral health disparities SGM individuals populations Research reduce oral health disparities SGM individuals populations, targeting individual, family, community, provider, health system, and/or policy levers change NIDDKsupports medical research research training dissemination science-based information diabetes other endocrine metabolic diseases; digestive diseases, nutritional disorders, obesity; kidney, urologic, hematologic diseases, improve peoples health quality life. Areas programmatic interest toNIEHSinclude are limited to: Studies better understand impact environmental exposures, such endocrine disrupting chemicals, gonadal development other hormonal systems affect sexual development Development resources, approaches, technologies will promote research environmental conditions effect health sexual gender minority populations Areas programmatic interest toNIMHinclude: Identification mutable mechanistic causes disparities mental health-related clinical including suicide thoughts behaviors) functional outcomes including Severe Mental Illness) which interventions targeting health equity be developed tested. could include interventions the individual, family, provider, clinic system-level, based the empirical evidence the contributing factor(s). Descriptive studies the prevalence characteristics mental disorders SGM individuals considered low priority. more details NIMH support intervention studies, please see:https://www.nimh.nih.gov/funding/opportunities-announcements/clinical-t…. Studies how non-mental health specialty settings e.g., SGM social support groups, human resources employee assistance programs, educational settings, etc.) contribute and support screening, referral, diagnosis treatment prevention mental illness suicide behavior SGM populations. development testing stigma reduction interventions and/or interventions address social cultural barriers not only change knowledge/attitudes/beliefs also lead behavior change consumers providers) structural change the clinic system level) improves access, engagement, retention, treatment adherence, quality care mental health outcomes including suicide risk) SGM across life course. Studies proposing adapt/augment interventions SGM racial ethnic minority groups should provide empirical basis the need intervention tailoring how is expected achieve equity mental health-related outcomes among those groups. Studies better understand disparities HIV rates outcomes among SGM living HIV how mitigate as well a better understanding the factors impeding scale of efficacious HIV prevention interventions SGM the development approaches address barriers. NIMHalso seeks studies that: Include sufficient numbers SGM individuals enable robust sub-group analyses. Conduct secondary data analyses identify strategies improving quality mental health care SGM individuals. Areas programmatic interest toNINDSinclude are limited to: Research health disparities SGM populations relevant neurological disorders fall within scientific mission the NINDS https://www.ninds.nih.gov/About-NINDS/Who-We-Are/Mission). Research the effects exogenous hormone among transgender and/or intersex individuals neurological function neurological disorders. Research risk factors neurological disorders SGM populations. Inquiries Please direct inquiries to: Jennifer Alvidrez, PhD National Institute Minority Health Health Disparities NIMHD) Telephone: 301-594-9567 Email:jennifer.alvidrez@nih.gov Della B. White, PhD National Center Complementary & Integrative Health NCCIH) Telephone: 301-827-6358 Email:Della.White@nih.gov Elizabeth Perruccio, PhD National Cancer Institute NCI) Telephone: 240-276-6178 Email:liz.perruccio@nih.gov Christine Gatlin, Ph.D. National Human Genome Research Institute NHGRI) Telephone: 301-480-2280 Email:gatlincl@mail.nih.gov Brad Newsome, PhD National Heart, Lung, Blood Institute NHLBI) Telephone: 301-827-8170 Email:brad.newsome@nih.gov Melissa S. Gerald, PhD National Institute Aging NIA) Telephone: 301-496-3136 Email:melissa.gerald@nih.gov Robert C. Freeman, PhD National Institute Alcohol Abuse Alcoholism NIAAA) Telephone: 301-443-8820 Email:rfreeman@mail.nih.gov Philip Renzullo, PhD, MPH National Institute Allergy Infectious Diseases NIAID) Telephone: 240-627-3041 Email:prenzullo@niaid.nih.gov Heiyoung Park, PhD National Institute Arthritis Musculoskeletal Skin Diseases NIAMS) Telephone: 301-594-3507 Email:Heiyoung.Park@nih.gov Regina Bures, PhD Eunice Kennedy ShriverNational Institute Child Health Human Development NICHD) Telephone: 301-496-9485 Email:regina.bures@nih.gov Jeffrey Schulden, MD National Institute Drug Abuse NIDA) Telephone: 301-402-1526 Email:schuldenj@nida.nih.gov Dena Fischer, DDS, MSD, MS National Institute Dental Craniofacial Research NIDCR) Telephone: 301-594-4876 Email:dena.fischer@nih.gov Tamara Bavendam, MD, MS National Institute Diabetes Digestive Kidney Diseases NIDDK) Telephone: 301-594-4733 Email:bavendamtg@mail.nih.gov Thaddeus Schug, PhD National Institute Environmental Health Sciences NIEHS) Telephone: 984-287-3319 Email:schugt2@niehs.nih.gov Tamara Lewis-Johnson, MBA, MPH National Institute Mental Health NIMH) Telephone: 301-594-7963 Email:tamara.lewisjohnson@nih.gov Richard T. Benson, MD, PhD National Institute Neurological Disorders Stroke NINDS) Phone: 301-496-9135 E-mail: Richard.benson@nih.gov Kate Winseck, MSW Office Disease Prevention ODP) Telephone: 301-827-5583 Email:winseckk@mail.nih.gov Victoria Cargill, MD, MSCE, AAHIVS Office Research Womens Health ORWH) Telephone: 301-435-0971 Email:cargillv@od.nih.gov Karen L. Parker, PhD, MSW Sexual & Gender Minority Research Office SGMRO) Telephone: 301-451-2055 Email:Klparker@mail.nih.gov